The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems
Topics: Economics, P&T Committee
16 Results
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
Topics: Economics, Rheumatology
The U.S. Generic & Biosimilar Medicines Savings Report (Sep. 2022)
Topics: Economics
The Global Use of Medicines 2023
Topics: Economics
National trends in prescription drug expenditures and projections for 2022
Topics: Economics
Projected US Savings From Biosimilars, 2021-2025
Topics: Economics
Biosimilars – Providing Affordable, Accessible Care for Patients
Topics: Economics, Implementation
Cost Savings with Biosimilars in Rheumatology: A Systematic Literature Search of Budget Impact Analysis
Topics: Economics
BIosimilar Report 2023 (Cardinal)
Topics: Economics
A health economic guide to market access of biosimilars
Topics: Economics
Biosimilars at 10 Years
Topics: Economics
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
Topics: Economics
Factors influencing the economics of biosimilars in the US
Topics: Economics
Rationale, Opportunities, and Reality of Biosimilar Medications
Topics: Economics
How to select a best-value biological medicine? A practical model to support hospital pharmacists
Topics: Economics, Implementation
Page 1 of 1